MenoGeniX is a women’s health care company focused on the clinical development of a biopharmaceutical alternative to FDA-approved hormone therapies and anti-depressants to treat hot flashes and related vasomotor symptoms of naturally occurring and surgically induced menopause.
MenoGeniX is a privately-held, clinical stage biopharmaceutical company, dedicated to researching and developing a novel potential treatment for women suffering from hot flashes and related vasomotor symptoms of menopause.
MenoGeniX is committed to developing MNGX-100 to provide a potential alternative therapy for women with either naturally occurring or surgically induced menopause who suffer from moderate and severe hot flashes and other vasomotor symptoms.
Over 10 million women aged 50-65 in the U.S. experience hot flashes due to naturally occurring menopause. Only two FDA-approved medications are currently available to treat the symptoms of menopause, hormone therapy and a low-dose form of the generic anti-depressant paroxetine. There is an unmet medical need for an alternative therapy for menopausal symptoms for women who are unwilling or unable to take the approved therapies.
